A new study shows that obese adults can lose weight with a drug recently approved by the Food and Drug Administration (FDA).
The study, published in the New England Journal of Medicine, found that adults who were overweight or obese who took the drug terzepeptide once a week were able to lose between 35 and 52 pounds.
The results showed that participants who received the 5 mg dose lost an average of 35 pounds. The participants who took the 10 milligram dose lost an average of 49 pounds.
According to the Centers for Disease Control and Prevention (CDC), weight above what is considered healthy for a given height is described as being overweight or obese.
Nearly 1 in 3 adults in the United States is overweight. According to the Centers for Disease Control and Prevention (CDC), the number of obese adults remained high during the pandemic in 2020, with the prevalence of adult obesity in 16 states at or above 35%.
People who are obese are more likely to have medical problems, such as type 2 diabetes, heart disease, stroke, and certain types of cancer.
Type 2 diabetes, the most common form of diabetes, is a serious health problem in the United States as well. More than 37 million Americans have diabetes and about 90-95% of them have type 2 diabetes, according to the CDC.
What is terzepeptide?
Tirzepatide, sold under the brand name Mounjaro, is a prescription medication used to treat type 2 diabetes in adults.
The drug was approved by the US Food and Drug Administration in May 2022, as an injectable drug to improve blood sugar control. According to the FDA statement, when combined with diet and exercise, the drug has been effective in helping to improve blood sugar levels.
The medicine is not used to treat adults with type 1 diabetes.
What side effects can people take?
Adults taking monjaro may have the following side effects:
- lack of appetite
- Abdominal discomfort
- Stomach ache
Who can take TIRZEPATIDE?
Terzepeptide is not currently approved for weight loss, but is intended to treat type 2 diabetes. The drug carries a warning about thyroid tumors and should not be used by people with a family history of certain thyroid conditions or patients with multiple endocrine neoplasia type 2 syndrome.